"Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a good deal of uncertainty in the markets. In fact, in the latest agreement, some Democrats and Republicans finally reached a vote of 60 to 40 to advance the vote to the next stage. Now we wait for it to pass the House. While we wait for that to happen, here's what analysts are pounding the table over."
"Nvidia (NASDAQ: NVDA): Ahead of Nvidia earnings next week, analysts at Citi reiterated a buy rating on the stock, with a price target of $220 from $210. The firm expects NVDA to post sales of $56.8 billion, as compared to analyst expectations for $54.6 billion. Analysts at Bank of America just reiterated a buy rating on Nvidia. The firm says NVDA is well-positioned for healthcare and artificial intelligence."
"Sunrun (NASDAQ: RUN): Analysts at Guggenheim just upgraded RUN to a buy, noting that it's compelling at current levels. With a $27 price target, the firm believes the stock's weakness is providing an attractive entry point, adding that prospects for capital returns in 2026 are solid. In early October, analysts at Jefferies upgraded RUN to a buy with a price target of $21 from $11."
Markets rallied as prospects of ending the government shutdown reduced uncertainty, with lawmakers advancing a 60-to-40 procedural vote and awaiting House passage. Citi, Bank of America, and UBS expressed confidence in Nvidia's positioning, forecasting higher sales and guiding fourth-quarter revenue toward $63–$64 billion while raising price targets. Guggenheim, Jefferies, and BMO upgraded Sunrun, citing attractive valuation, expected strong cash generation, and potential for capital returns including buybacks or dividends. Leerink upgraded Eli Lilly. Analysts focused on earnings, revenue guidance, and future cash returns as drivers of bullish sentiment.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]